CellaVision ABCVLLY +12.06%69 Days Payable is 66.63 as of Mar. 2026, which is 3% below its 10-year median of 68.86. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 795 Medical Devices & Instruments companies, CellaVision AB ranks worse than 55.47% on this metric.
The historical rank and industry rank for CellaVision AB's Days Payable or its related term are showing as below:
CVLLY'
s Days Payable Range Over the Past 10 Years
Min: 49.06 Med: 68.86 Max: 93.72
Current: 62.92
During the past 13 years, CellaVision AB's highest Days Payable was 93.72. The lowest was 49.06. And the median was 68.86.
CVLLY's Days Payable is ranked worse than 55.47% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs CVLLY: 62.92
CellaVision AB's Days Payable
increased
from Mar. 2025 (56.67) to Mar. 2026 (66.63).
It may suggest that CellaVision ABdelayed paying its suppliers.
CellaVision AB Days Payable Related Terms
CellaVision AB Days Payable Historical Data
* Premium members only.
The historical data trend for CellaVision AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CellaVision AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Days Payable distribution charts can be found below:
* The bar in red indicates where CellaVision AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
CellaVision AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellaVision AB (CVLLY) has a Days Payable of 66.63 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CellaVision AB and its competitors. This is near median its historical median of 68.86. Over the past decade, CellaVision AB's Days Payable has ranged from 49.06 to 93.72. According to the industry distribution chart, CellaVision AB ranks #441 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 55.5%.
Is CellaVision AB's Days Payable too high?
CellaVision AB's current Days Payable of 66.63 is near median its 10-year median of 68.86. Over the past 10 years, this metric has ranged from a low of 49.06 to a high of 93.72. The Medical Devices & Instruments industry median Days Payable is 67.87. CellaVision AB's value of 66.63 is 1.8% below this industry median. Based on the distribution chart, CellaVision AB ranks #441 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #441 out of 795 companies for Days Payable. This places CellaVision AB in the lower half of its industry. The industry median Days Payable is 67.87. CellaVision AB's value of 66.63 is 1.8% below this benchmark. Historically, CellaVision AB's own Days Payable has ranged from 49.06 to 93.72 over the past decade. While the company's 10-year median is 68.86 vs. the industry median of 67.87, CellaVision AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current Days Payable of 66.63 is 1.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current Days Payable is 66.63, which is near median its own 10-year median of 68.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current Days Payable is 66.63, which is near median its 10-year median of 68.86 and 1.8% below the Medical Devices & Instruments industry median of 67.87. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current Days Payable is 66.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CVLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CVLLY:
Days Payable: 66.63 (near median its 10-year median of 68.86)
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
Industry Position: 1.8% below the Medical Devices & Instruments median (#441 of 795)
No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score
Get the complete analysis for CVLLY
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVLLY has been successfully added to your 
